Orexo Q2 2023 Interim Report
The patent win critical enabler for future growth Q2 2023 highlights› Total net revenues of SEK 157.7 m (147.8)› EBITDA of SEK 5.6 m (-32.5), EBITDA excluding legal costs and costs for non-repeating clinical trials, SEK 30.3 m (11.4) › Net earnings of SEK -12.6 m (-35.8)› US Pharma segment (ZUBSOLV® US) net revenues of SEK 145.4 m (139.6), in local currency USD 13.8 m (14.2), US Pharma EBIT of SEK 71.2 m (77.2)› Cash flow from operating activities of SEK -12.7 m (14.5), cash and invested funds of SEK 251.1 m (467.7)› Earnings per share before and